文献速递眼整形与眼眶神经眼科

接受替妥木单抗治疗患者听力功能障碍的发生频率与模式

Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab.
PubMed 文献 · Ophthalmology · 2023-08-09

非比较性病例系列纳入22例(44耳)接受替妥木单抗治疗的甲状腺眼病患者,治疗前后听力测试显示17耳(38.6%)符合耳毒性标准,11例(50.0%)至少1耳受累;纯音平均听阈在治疗后下降,主要累及高频和中频,低频无显著变化,年龄较大者更易出现听力损失。

要点

  • 22例患者中11例(50.0%)至少1耳符合耳毒性标准,44耳中17耳(38.6%)符合。
  • 治疗后纯音平均听阈下降(P=0.0029),高频(P=0.0008)和中频(P=0.0042)受累,低频无显著变化(P=0.8344)。
  • 年龄较大患者治疗后更易出现听力损失(P=0.0048)。

核心结论

  • 听力学数据表明替妥木单抗影响听力功能,最显著累及较高频率和年龄较大的患者。
  • 听力学检测对于替妥木单抗治疗的患者咨询至关重要。
  • 需要制定治疗期间听力监测方案以发现和管理替妥木单抗相关的听力变化。

研究设计与样本

  • 非比较性病例系列,纳入替妥木单抗输注前后完成听力学检测的患者。
  • 共纳入22例患者(44耳),基线及治疗后最近一次听力学检测时间范围为治疗前84天至治疗后496天。
  • 15例患者(30耳)在治疗期间(第二次输注后至第八次输注当天但输注前)也接受了检测。

主要发现

  • 治疗后44耳中17耳(38.6%)符合耳毒性标准,22例中11例(50.0%)至少1耳符合。
  • 全部44耳纯音平均听阈在治疗后下降(P=0.0029),高频(P=0.0008)和中频(P=0.0042)下降,低频无显著变化(P=0.8344)。
  • 年龄较大的患者治疗后更易出现听力损失(P=0.0048)。

临床怎么用

  • 听力学检测对于替妥木单抗治疗的患者咨询至关重要。
  • 需要制定治疗期间听力监测方案以发现和管理替妥木单抗相关的听力变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To better characterize the frequency and patterns of hearing dysfunction in patients who have received teprotumumab to treat thyroid eye disease. DESIGN: Noncomparative case series. PARTICIPANTS: Patients who underwent audiology testing before and after completion of teprotumumab infusions. METHODS: A review of patients who underwent audiology testing before and after completion of teprotumumab infusions was carried out. Additional audiogram testing during treatment was included when available. Hearing function was analyzed using audiogram data measuring threshold hearing levels at specific frequencies. Basic demographic data as well as information regarding otologic symptoms also were obtained and analyzed. MAIN OUTCOME MEASURES: Hearing loss demonstrated by a significant change in decibel hearing thresholds or that meets criteria for ototoxicity. RESULTS: Twenty-two patients (44 ears) were included in the study, with baseline and most recent audiology testing after treatment ranging from 84 days before to 496 days after treatment. Fifteen patients (30 ears) also underwent testing during treatment starting after the second infusion up until the day of, but before, the eighth infusion. Hearing loss after treatment met criteria for ototoxicity in 17 of the 44 ears (38.6%), with 11 of the 22 patients (50.0%) meeting criteria in at least 1 ear. The pure-tone average decibel hearing levels (HLs) across all 44 ears demonstrated hearing loss after treatment (P = 0.0029), specifically at high (P = 0.0008) and middle frequencies (P = 0.0042), but not at low frequencies (P = 0.8344). Patients who were older also were more likely to experience hearing loss after treatment (P = 0.0048). CONCLUSIONS: Audiometric data demonstrate that teprotumumab influences hearing function, most significantly at higher frequencies and in older patients. Audiometric testing is critical for counseling patients regarding teprotumumab treatment. A protocol for monitoring hearing during treatment is needed to detect and manage hearing changes associated with teprotumumab use. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Keen JA, Correa T, Pham C, et al. Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab. Ophthalmology. 2023. PMID: 37567417. doi:10.1016/j.ophtha.2023.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。